Related Experiment Videos
Therapeutic management of acute myocardial infarction
1University of Utah, Division of Cardiology, LDS Hospital, Salt Lake City 84143.
Insights
Thrombolytic therapy is effective for acute myocardial infarction (AMI) in selected patients, improving coronary perfusion, ventricular function, and survival. Careful patient selection and management, including ancillary therapies, are crucial despite bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary thrombosis is central to acute myocardial infarction (AMI) pathogenesis.
- Thrombolytic therapy aims to restore coronary perfusion, a critical intervention for AMI.
Purpose of the Study:
- To review criteria for selecting patients for thrombolytic therapy.
- To discuss benefits and management of approved thrombolytic agents for AMI.
- To explore ancillary therapies and interventional strategies in AMI management.
Main Methods:
- Review of studies on thrombolytic therapy endpoints: coronary patency, left ventricular function, and mortality reduction.
- Evaluation of streptokinase, alteplase, and anistreplase for intravenous use in AMI.
- Discussion of bleeding risks and ancillary treatments like aspirin and heparin.
Main Results:
- Thrombolytic therapy is established for specific AMI patients (brief ischemic pain, ST-elevation, <75 years, no contraindications).
- Benefits include improved coronary artery patency, enhanced left ventricular function, and reduced mortality.
- Approved agents (streptokinase, alteplase, anistreplase) show benefits, but none is clearly superior; bleeding risk is a concern.
Conclusions:
- Thrombolytic therapy is a promising treatment for selected AMI patients.
- Ancillary therapies and a conservative approach to interventions are generally supported.
- Ongoing research aims to identify the optimal thrombolytic agent and management strategy for AMI.
Abstract:
Criteria for selecting patients for thrombolytic therapy are presented, the major benefits of the currently approved thrombolytic agents are reviewed, and management considerations, including contraindications and the role of ancillary therapy, are discussed. Coronary thrombosis is now believed to play a central role in the pathogenesis of acute myocardial infarction (AMI). Re-establishment of coronary perfusion by thrombolysis has been extensively studied in the past decade and is now regarded as established therapy for patients with ischemic pain of brief (less than six hours') duration who have electrocardiographic ST-segment elevation, are less than 75 years of age, and have no contraindications. Studies supporting thrombolytic therapy have focused on the endpoints of (1) coronary artery patency or reperfusion, (2) improvement in left ventricular function, and (3) reduction in mortality. Benefits for each of these three endpoints have been established and are reviewed with respect to streptokinase, alteplase, and anistreplase, the three agents that have been approved for intravenous use in patients with AMI. The risk of bleeding, including intracranial hemorrhage, remains a concern for all patients. Ancillary therapies to be considered include aspirin, heparin, nitroglycerin, and beta blockers. Recent studies testing different strategies for coronary angiography and angioplasty plus surgery have generally supported a conservative approach, with interventions performed for clinical reasons rather than prophylaxis. Although the currently approved agents have differing pharmacologic profiles, none has yet proved to be clearly superior in the management of patients with AMI. Nonetheless, these agents remain the most promising means of treating selected patients.